Results 11 to 20 of about 9,064,090 (287)

Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery

Molecular Cancer, 2006
Background Treatment of cells with the anti-cancer drug 5-fluorouracil (5-FU) causes DNA damage, which in turn affects cell proliferation and survival.
Kravik Katherine L, Svendsrud Debbie H, De Angelis Paula M, Stokke Trond   +3 more
doaj   +2 more sources

Aspirin suppresses chemoresistance and enhances antitumor activity of 5-Fu in 5-Fu-resistant colorectal cancer by abolishing 5-Fu-induced NF-κB activation [PDF]

Scientific Reports, 2019
AbstractChemoresistance to 5-fluorouracil (5-Fu)-based chemotherapy is a leading obstacle in achieving effective treatment for colorectal cancer (CRC). Typically, NF-κB activation induced by the chemotherapeutics themselves is an important cause resulting in chemoresistance.
Fu Jinbo, Xu Yiming, Yang Yushan, Liu Yun, Ma Lulu, Zhang Yiyao   +5 more
openaire   +5 more sources

Association of 5-FU Therapeutic Drug Monitoring to DPD Phenotype Assessment May Reduce 5-FU Under-Exposure

Pharmaceuticals, 2020
In order to limit 5-fluorouracil (5-FU) toxicity, some health agencies recommend evaluating dihydropyrimidine dehydrogenase (DPD) deficiency before any 5-FU treatment introduction.
Marine Dolat, Pauline Macaire, Françoise Goirand, Julie Vincent, Audrey Hennequin, Rémi Palmier, Leïla Bengrine-Lefevre, François Ghiringhelli, Bernard Royer, Antonin Schmitt   +9 more
doaj   +2 more sources

Uio-68-5-FU as a drug delivery platform for 5-FU

, 2022
The drug delivery application of Porous metal–organic frameworks (MOFs) have been investigated due to their unique structures which are built of inorganic nodes and organic ligands. In present study, Uio-68-5-FU was successfully prepared by applied for delivery of 5-fluorouracil (5-FU).
Pourya Zarshenas
openaire   +3 more sources

Protracted infusional 5-fluorouracil (5-FU) with bolus mitomycin in 5-FU-resistant colorectal cancer

Annals of Oncology, 2000
MF (protracted infusion 5-fluorouracil (5-FU), 300 mg/m2/24 hours plus bolus mitomycin, 7 mg/m2 every 6 weeks, maximum 4 doses), was recently shown in a randomised trial to be superior to protracted 5-FU alone, as first-line chemotherapy for metastatic colorectal cancer (Ross et al. Ann Oncol 1997; 8: 995-1001 [5]). We have examined the same regimen in
J D, Chester, J T, Dent, G, Wilson, E, Ride, M T, Seymour   +4 more
openaire   +3 more sources

Kinetic modeling of 5-FU-loaded SLNs.

, 2023
The present study aimed to prepare solid lipid-based nanoparticles (SLNs) using Precirol® ATO 5 as solid lipid and Poloxamer 188 and Tween 80 as surfactant and co-surfactant respectively, and SLNs-derived gel for sustained delivery, enhanced in-vitro ...
Muhammad Ahmad Mahmood (14691670), Hassan Shah (10731562), Muhammad Muzamil Khan (14691667), Talha Jamshaid (13488061), Nasrullah Jan (10731559), Ahsan Ali (6478244), Safiullah Khan (10731565), Asadullah Madni (9389400)   +7 more
core   +1 more source

Rheograms of 5-FU plain gel and 5-FU-loaded SLNs gel.

, 2023
Rheograms of 5-FU plain gel and 5-FU-loaded SLNs gel.
Muhammad Ahmad Mahmood (14691670), Hassan Shah (10731562), Muhammad Muzamil Khan (14691667), Talha Jamshaid (13488061), Nasrullah Jan (10731559), Ahsan Ali (6478244), Safiullah Khan (10731565), Asadullah Madni (9389400)   +7 more
core   +1 more source

Permeation analysis of 5-FU-loaded SLNs gel and 5-FU plain gel.

, 2023
Permeation analysis of 5-FU-loaded SLNs gel and 5-FU plain gel.
Muhammad Ahmad Mahmood (14691670), Hassan Shah (10731562), Muhammad Muzamil Khan (14691667), Talha Jamshaid (13488061), Nasrullah Jan (10731559), Ahsan Ali (6478244), Safiullah Khan (10731565), Asadullah Madni (9389400)   +7 more
core   +1 more source

Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial [PDF]

, 2006
Oral capecitabine (Xeloda^®) is an effective drug with favourable safety in adjuvant and metastatic colorectal cancer.
F Coxon, T S Maughan, Douillard, J.Y., Lesniewski-Kmak, K, Bertetto, O., Jelic, S., Maughan, T.S., Dufour, A., J-Y Douillard, Johnston, P G, C Twelves, Díaz-Rubio, E., Cassidy, J, Twelves, C., Jelic, S, P G Johnston, Figer, A, G Fountzilas, W Scheithauer, Patel, K K, Malzyner, A, Fountzilas, G., K Lesniewski-Kmak, A Malzyner, Maughan, TS, Bustová, I, Cowell, W., Garrison, L.P., Twelves, C, Díaz-Rubio, E, O Bertetto, W Cowell, Beham, A, S Jelic, Maughan, Tim, Dufour, P, J J McKendrick, Scheithauer, W., Douillard, JY, Cowell, W, Lesniewski-Kmak, K., Garrison, L P, Bustová, I., Beham, A., Fountzilas, G, Johnston, PG, A Beham, Garrison, LP, K K Patel, Patel, KK, I Bustová, Cassidy, J., McKendrick, J.J., Bertetto, O, L P Garrison, Coxon, F., Patel, K.K., Douillard, J-Y, P Dufour, A Figer, Johnston, P.G., Scheithauer, W, Coxon, F, Maughan, T S, McKendrick, JJ, J Cassidy, E Díaz-Rubio, McKendrick, J J, Malzyner, A., Figer, A.   +69 more
core   +1 more source

Ex-vivo permeation analysis of 5-FU-loaded SLNs gel and 5-FU plain gel.

, 2023
Ex-vivo permeation analysis of 5-FU-loaded SLNs gel and 5-FU plain gel.
Muhammad Ahmad Mahmood (14691670), Hassan Shah (10731562), Muhammad Muzamil Khan (14691667), Talha Jamshaid (13488061), Nasrullah Jan (10731559), Ahsan Ali (6478244), Safiullah Khan (10731565), Asadullah Madni (9389400)   +7 more
core   +1 more source